Phaseline

Targets › FGFR1

FGFR1 (Fibroblast growth factor receptor 1): drug programs, companies and trials

36 programs from 32 companies in 162 trials: 108 Phase 2, 38 Phase 1, 15 Phase 3, 1 Phase 4; Oncology, Gastroenterology, Metabolic and endocrine; next expected readout Nov 2026.

Tyrosine-protein kinase that acts as a cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of embryonic development, cell proliferation, differentiation and migration. Required for normal mesoderm patterning and correct axial organization during embryonic development, normal skeletogenesis and normal development of the gonadotropin-releasing hormone (GnRH) neuronal…. (UniProt, P11362)

Open in Phaseline: the race on FGFR1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
TransThera Sciences (Nanjing)TT-00420 (tinengotinib)
Fibroblast growth factor receptor (FGFR) inhibitor
FGFR1, FGFR2, FGFR3, FGFR4Phase 3Cholangiocarcinoma; Cholangiocarcinoma Metastatic; Breast Cancer; Prostate Cancer (CRPC)Dec 2026
ExelixisZanzalintinib (XL092)
Multi-targeted tyrosine kinase inhibitor targeting FGFR, MET, ROS1, and AXL
FGFR1, FGFR2, FGFR3, FGFR4, MET, KIT, PDGFRAPhase 3Non-Clear Cell Renal Cell Carcinoma; Colorectal Cancer; Meningioma; Head and Neck Squamous Cell Carcinoma …Dec 2026
Xynomic PharmaceuticalsPazopanib
Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase LCK inhibitor
CSF1R, KIT, LCK, FGFR3, FGFR1Phase 3Renal Cell Carcinoma; Leiomyosarcoma or Carcinosarcoma; Soft Tissue Sarcoma; Rhabdomyosarcoma, Recurrent, Refractory …Dec 2026
Johnson & Johnson (Janssen)Erdafitinib (TAR-210)
Fibroblast growth factor receptor inhibitor
FGFR3, FGFR1, FGFR4, FGFR2Phase 3Urothelial Cancer; Non-Muscle Invasive Bladder Neoplasms; Urothelial Carcinoma; Advanced Malignant Solid Neoplasm …Dec 2026
National Cancer Institute (NCI)Pazopanib Hydrochloride
Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase LCK inhibitor
CSF1R, KIT, LCK, FGFR3, FGFR1Phase 3Clear Cell Renal Cell Carcinoma; Foregut Neuroendocrine Tumor; Solid NeoplasmFeb 2027
Taiho OncologyFutibatinib (TAS-120)
Fibroblast growth factor receptor inhibitor
FGFR3, FGFR1, FGFR4, FGFR2Phase 2Advanced Cholangiocarcinoma; Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer; Advanced/Metastatic Cancer; Biliary Tract Neoplasms …Dec 2026
Tianjin Medical University Cancer Institute and HospitalPemigatinib
Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor
FGFR2, FGFR3, FGFR1Phase 2Gastrointestinal CancerDec 2026
Fei GaoDonafenib
Multi-kinase inhibitor targeting FGFR and VEGFR
FGFR1, VEGFR1, VEGFR2, VEGFR3Phase 2Hepatocellular Carcinoma with PVTTDec 2026
Shanghai Zhongshan HospitalHRS-4642
FGFR1/2/3/4 inhibitor
FGFR1, FGFR2, FGFR3, FGFR4Phase 2Biliary Tract Cancer; Pancreatic CancerDec 2026
Sameek RoychowdhuryPemigatinib
Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor
FGFR2, FGFR3, FGFR1Phase 2Advanced Pancreatic CarcinomaDec 2026
University of UtahPemigatinib
Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor
FGFR2, FGFR3, FGFR1Phase 2Relapsed or Refractory B-cell Non-Hodgkin LymphomaMar 2027
Shanghai Zhongshan HospitalHEC88473
GLP-1/FGF21 dual agonist
GLP1R, FGFR1Phase 2PCOS (Polycystic Ovary Syndrome)Jun 2027
UNICANCERPemigatinib
Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor
FGFR2, FGFR3, FGFR1Phase 2Solid Tumor, MiscellaneousJun 2027
Mehmet AkcePemigatinib
Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor
FGFR2, FGFR3, FGFR1Phase 2Intrahepatic CholangiocarcinomaJul 2027
National Cancer Institute (NCI)Rogaratinib
Fibroblast growth factor receptor inhibitor
FGFR3, FGFR1, FGFR4, FGFR2Phase 2Locally Advanced Gastrointestinal Stromal TumorJul 2027
Ohio State University Comprehensive Cancer CenterPemigatinib
Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor
FGFR2, FGFR3, FGFR1Phase 2Locally Advanced Ampulla of Vater CarcinomaDec 2027
Haitao Zhao, MDPemigatinib
Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor
FGFR2, FGFR3, FGFR1Phase 2Biliary Tract Cancer (BTC)Dec 2027
Lund University HospitalPemigatinib
Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor
FGFR2, FGFR3, FGFR1Phase 2Dedifferentiated LiposarcomaDec 2027
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyDonafenib
Multi-kinase inhibitor with activity against FGFRs, VEGFR, and RET
FGFR1, FGFR2, FGFR3, FGFR4Phase 2Hepatocellular CarcinomaJan 2028
National Cancer Center, JapanE7090
FGFR inhibitor
FGFR1, FGFR2, FGFR3, FGFR4Phase 2Advanced or Recurrent Solid TumorsMar 2028
BayerRegorafenib (BAY73)
Tyrosine-protein kinase ABL inhibitor; Serine/threonine-protein kinase RAF inhibitor; Stem cell growth factor receptor inhibitor
ABL1, RAF1, KIT, FGFR1, MAPK11Phase 2Solid Malignant Tumors; Metastatic Colorectal Cancer (mCRC); Colorectal Cancer Liver Metastases; Colorectal Cancer Metastatic …Apr 2028
HutchmedSurufatinib
Fibroblast growth factor receptor 1 inhibitor; Vascular endothelial growth factor receptor inhibitor
FGFR1, FLT1, FLT4, KDRPhase 2Metastatic Pancreatic Cancer; Neuroendocrine Tumors; Pancreatic Cancer, Adult; Intrahepatic Cholangiocarcinoma …May 2028
HutchmedHmpl-453 (HMPL-453)
Fibroblast growth factor receptor 1 inhibitor; Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor
FGFR1, FGFR2, FGFR3Phase 2Advanced Intrahepatic CholangiocarcinomaJun 2028
Dana-Farber Cancer InstitutePemigatinib (INCB054828)
Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor
FGFR2, FGFR3, FGFR1Phase 2SDH Gene MutationOct 2028
QED Therapeutics, a BridgeBio companyInfigratinib
Fibroblast growth factor receptor inhibitor
FGFR3, FGFR1, FGFR4, FGFR2Phase 2AchondroplasiaMar 2030
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestDerazantinib
Fibroblast growth factor receptor inhibitor
FGFR3, FGFR1, FGFR4, FGFR2Phase 2Intrahepatic Cholangiocarcinoma–
Biohaven TherapeuticsTaldefgrobep Alfa
FGF21 receptor agonist (FGF21 analog)
FGFR1, FGFR4, KLBPhase 2Obesity–
AstraZenecaFexagratinib (AZD4547)
Fibroblast growth factor receptor inhibitor
FGFR3, FGFR1, FGFR4, FGFR2Phase 1Muscle Invasive Bladder Cancer; Metastatic Breast CancerNov 2026
OHSU Knight Cancer InstitutePemigatinib
Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor
FGFR2, FGFR3, FGFR1Phase 1Acute Myeloid LeukemiaDec 2026
Kidney Cancer Research BureauOM-RCA-01
humanized monoclonal anti-FGFR1 antibody
FGFR1Phase 1Renal Cell Carcinoma MetastaticJan 2027
Tyra BiosciencesTYRA-200
FGFR 1/2/3 tyrosine kinase inhibitor
FGFR1, FGFR2, FGFR3Phase 1Locally Advanced CholangiocarcinomaMar 2027
EisaiE-7090 (E7090)
Fibroblast growth factor receptor 1 inhibitor; Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor
FGFR1, FGFR2, FGFR3Phase 1Hepatic ImpairmentAug 2027
Massachusetts General HospitalPemigatinib
Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor
FGFR2, FGFR3, FGFR1Phase 1Advanced Solid TumorDec 2027
Tyra BiosciencesTYRA-430
FGFR inhibitor
FGFR1, FGFR2, FGFR3, FGFR4Phase 1Metastatic Hepatocellular CarcinomaJan 2028
M.D. Anderson Cancer CenterPemigatinib
Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor
FGFR2, FGFR3, FGFR1Phase 1Advanced CholangiocarcinomaFeb 2028
RocheGDC-4198
FGFR1 inhibitor
FGFR1Phase 1Breast CancerAug 2028

Conditions

Hepatocellular Carcinoma (5) Colorectal Cancer (5) Non-Muscle Invasive Bladder Neoplasms (3) Intrahepatic Cholangiocarcinoma (3) Urothelial Cancer (2) Advanced Malignant Solid Neoplasm (2) Advanced Cholangiocarcinoma (2) Advanced Solid Tumor (2) Pancreatic Cancer (2) Hepatic Impairment (2) Breast Cancer (2) Colorectal Cancer Metastatic (2)

Modalities

small molecule (23), mixed (10), antibody (2), protein or peptide (1)

Companies

Shanghai Zhongshan Hospital (2) Tyra Biosciences (2) National Cancer Institute (NCI) (2) Hutchmed (2) AstraZeneca (1) Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1) Johnson & Johnson (Janssen) (1) Taiho Oncology (1) Massachusetts General Hospital (1) Exelixis (1) UNICANCER (1) Kidney Cancer Research Bureau (1) QED Therapeutics, a BridgeBio company (1) National Cancer Center, Japan (1) TransThera Sciences (Nanjing) (1) Mehmet Akce (1) Bayer (1) University of Utah (1) Tianjin Medical University Cancer Institute and Hospital (1) Fei Gao (1)

Related targets

FGFR3 (29) FGFR2 (27) FGFR4 (13) KIT (4) CSF1R (2) LCK (2) MET (1) PDGFRA (1) ABL1 (1) RAF1 (1) MAPK11 (1) GLP1R (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.